Lumacaftor-ivacaftor/Slt Strong CYP3A4 Inhibitor & Substrate Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines may slow down how quickly your liver processes ivacaftor. Lumacaftor may speed up how quickly your liver processes your other medicine.
What might happen:
The amount of ivacaftor in your blood may increase and cause more side effects than normally expected. The amount of your other medicine in your blood may decrease, and it may not work as well.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to change your medicines or adjust the dose of your lumacaftor-ivacaftor while your body is getting adjusted to this medicine combination. Let your doctor know right away if you have any pain or discomfort in the upper right stomach (abdominal) area, yellowing of the skin or eyes, loss of appetite, nausea or vomiting, or dark/amber-colored urine.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and- drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
- 2.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
- 3.Orkambi (lumacaftor, ivacaftor) US prescribing information. Vertex Pharmaceuticals Inc. August, 2023.
- 4.Liddy AM, McLaughlin G, Schmitz S, D'Arcy DM, Barry MG. The Pharmacokinetic Interaction between Ivacaftor and Ritonavir in Healthy Volunteers. Br J Clin Pharmacol 2017 May 06.
- 5.Sporanox (itraconazole) US prescribing information. Janssen Pharmaceutica Products, L.P. February, 2024.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.